Skip to main content

Table 2 Suspected VAP episode description according to statin exposure and outcome

From: Impact of prior statin therapy on the outcome of patients with suspected ventilator-associated pneumonia: an observational study

  Overall Statin previous users Statin-naive patients P
(n = 349) (n = 93) (n = 256)
Time elapsed between ICU admission and VAP (days) 10.0 (2.0-157.0) 10.0 (2.0-72.0) 10.0 (2.0-157.0) 0.62
Time elapsed between MV onset and VAP (days) 10.0 (2.0-156.0) 10.0 (2.0-69.0) 10.0 (2.0-156.0) 0.48
Early VAP (n (%)) 108 (30.9) 27 (29.0) 81 (31.6) 0.64
Septic shock (n (%)) 117 (33.6) 35 (38.0) 82 (32.0) 0.29
Appropriate antibiotic therapy (n (%)) 262 (76.4) 70 (76.9) 192 (76.2) 0.89
Concurrent therapy during VAP period  
 Steroids (n (%)) 153 (45.0) 41 (45.1) 112 (45.0) 0.99
 RRT (n (%)) 83 (24.4) 29 (31.9) 54 (21.7) 0.05
CPIS D1 6.0 (2.0-11.0) 5.0 (2.0-9.0) 6.0 (2.0-11.0) 0.32
CPIS D3 7.0 (5.0-13.0) 7.0 (5.0-11.0) 7.0 (5.0-13.0) 0.25
SOFA D1 8.0 (4.0-17.01) 9.0 (4.0-16.0) 8.0 (4.0-17.0) 0.11
SOFA D3 8.0 (4.0-18.0) 8.0 (4.0-15.0) 8.0 (4.0-18.0) 0.63
PCT D-1 1.2 (0.1-172.0) 1.1 (0.1-55.9) 1.4 (0.1-172.0) 0.42
PCT D1 1.2 (0.1-91.4) 1.3 (0.1-30.0) 1.2 (0.1-91.4) 0.41
PCT D2 1.5 (0.1-162.0) 1.4 (0.1-64.3) 1.6 (0.1-162.0) 0.28
PCT D3 1.3 (0.1-345.2) 1.5 (0.1-56.2) 1.2 (0.1-345.2) 0.71
PCT D4 1.2 (0.1-199.2) 1.0 (0.1-35.3) 1.2 (0.1-199.2) 0.61
Ventilator-free days 4.0 (0.0-112.0) 2.0 (0.0-30.0) 4.0 (0.0-112.0) <0.01
Length of ICU stay (days) 26.0 (4.0-204.0) 25.0 (4.0-147.0) 26.0 (5.0-204.0) 0.80
Duration of MV (days) 20.0 (2.0-176.0) 20.0 (2.0-121.0) 19.0 (2.0-176.0) 0.42
30-day mortality (n (%)) 100 (28.6) 33 (35.5) 67 (26.2) 0.09
  1. VAP, ventilator-associated pneumonia; ICU, intensive care unit; MV, mechanical ventilation; RRT, renal replacement therapy; CPIS, clinical pulmonary infection score; D, day; SOFA, sequential organ failure assessment; PCT, procalcitonin.